Key facts
- This page summarizes Ronit Simantov's Form 4 filing for Clovis Oncology, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Jul 2021, 16:25.
Ronit Simantov - 12 Jul 2021 Form 4 Insider Report for Clovis Oncology, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 12 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jul 2021, 16:25:24 UTC
- Next SEC filing
- 10 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ronit Simantov
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ronit Simantov filed Form 4 for Clovis Oncology, Inc. on 13 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLVS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +83,212
- Change %
- Price
- $0.000000
- Shares after
- 83,212
- Date
- 12 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,212
- Exercise price
- $5.30
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant.